These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 34315786)

  • 21. Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development.
    Paganoni S; Berry JD; Quintana M; Macklin E; Saville BR; Detry MA; Chase M; Sherman AV; Yu H; Drake K; Andrews J; Shefner J; Chibnik LB; Vestrucci M; Cudkowicz ME;
    Ann Neurol; 2022 Feb; 91(2):165-175. PubMed ID: 34935174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stem cell treatments for amyotrophic lateral sclerosis: a critical overview of early phase trials.
    Goutman SA; Savelieff MG; Sakowski SA; Feldman EL
    Expert Opin Investig Drugs; 2019 Jun; 28(6):525-543. PubMed ID: 31189354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ALS clinical trials: do enrolled patients accurately represent the ALS population?
    Chiò A; Canosa A; Gallo S; Cammarosano S; Moglia C; Fuda G; Calvo A; Mora G;
    Neurology; 2011 Oct; 77(15):1432-7. PubMed ID: 21956723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study.
    Fang T; Al Khleifat A; Meurgey JH; Jones A; Leigh PN; Bensimon G; Al-Chalabi A
    Lancet Neurol; 2018 May; 17(5):416-422. PubMed ID: 29525492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison Of King's Clinical Staging In Multinational Amyotrophic Lateral Sclerosis Cohorts.
    Balendra R; Jones AR; Al Khleifat A; Chiwera T; Wicks P; Young CA; Shaw PJ; Turner MR; Leigh PN; Al-Chalabi A
    Amyotroph Lateral Scler Frontotemporal Degener; 2023 Feb; 24(1-2):71-81. PubMed ID: 35852375
    [No Abstract]   [Full Text] [Related]  

  • 26. Opportunities for improving therapy development in ALS.
    Bruijn L; Cudkowicz M;
    Amyotroph Lateral Scler Frontotemporal Degener; 2014 Jun; 15(3-4):169-73. PubMed ID: 24472060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials.
    van Eijk RPA; Westeneng HJ; Nikolakopoulos S; Verhagen IE; van Es MA; Eijkemans MJC; van den Berg LH
    Neurology; 2019 Jan; 92(5):e451-e460. PubMed ID: 30626653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial).
    Bella ED; Tramacere I; Antonini G; Borghero G; Capasso M; Caponnetto C; Chiò A; Corbo M; Eleopra R; Filosto M; Giannini F; Granieri E; Bella V; Lunetta C; Mandrioli J; Mazzini L; Messina S; Monsurrò MR; Mora G; Riva N; Rizzi R; Siciliano G; Silani V; Simone I; Sorarù G; Volanti P; Lauria G
    BMJ Open; 2017 Aug; 7(8):e015434. PubMed ID: 28801400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Item response theory analysis of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised in the Pooled Resource Open-Access ALS Clinical Trials Database.
    Bacci ED; Staniewska D; Coyne KS; Boyer S; White LA; Zach N; Cedarbaum JM;
    Amyotroph Lateral Scler Frontotemporal Degener; 2016; 17(3-4):157-67. PubMed ID: 26473473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease.
    Ng L; Khan F; Young CA; Galea M
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011776. PubMed ID: 28072907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repetitive transcranial magnetic stimulation for the treatment of amyotrophic lateral sclerosis or motor neuron disease.
    Guo J; Zhou M; Yang M; Zhu C; He L
    Cochrane Database Syst Rev; 2011 Sep; (9):CD008554. PubMed ID: 21901724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS.
    Goyal NA; Berry JD; Windebank A; Staff NP; Maragakis NJ; van den Berg LH; Genge A; Miller R; Baloh RH; Kern R; Gothelf Y; Lebovits C; Cudkowicz M
    Muscle Nerve; 2020 Aug; 62(2):156-166. PubMed ID: 31899540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in clinical trials for amyotrophic lateral sclerosis.
    Gordon PH
    Curr Neurol Neurosci Rep; 2005 Feb; 5(1):48-54. PubMed ID: 15676108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The value of database controls in pilot or futility studies in ALS.
    Czaplinski A; Haverkamp LJ; Yen AA; Simpson EP; Lai EC; Appel SH
    Neurology; 2006 Nov; 67(10):1827-32. PubMed ID: 17130417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS).
    Mandrioli J; Crippa V; Cereda C; Bonetto V; Zucchi E; Gessani A; Ceroni M; Chio A; D'Amico R; Monsurrò MR; Riva N; Sabatelli M; Silani V; Simone IL; Sorarù G; Provenzani A; D'Agostino VG; Carra S; Poletti A
    BMJ Open; 2019 May; 9(5):e028486. PubMed ID: 31152038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A retrospective investigation of the relationship between baseline covariates and rate of ALSFRS-R decline in ALS clinical trials.
    Daghlas I; Lever TE; Leary E
    Amyotroph Lateral Scler Frontotemporal Degener; 2018 May; 19(3-4):206-211. PubMed ID: 29260911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials.
    van Eijk RPA; Eijkemans MJC; Ferguson TA; Nikolakopoulos S; Veldink JH; van den Berg LH
    J Neurol Neurosurg Psychiatry; 2018 Feb; 89(2):156-161. PubMed ID: 29084868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis.
    van Eijk RP; Eijkemans MJ; Rizopoulos D; van den Berg LH; Nikolakopoulos S
    Clin Epidemiol; 2018; 10():333-341. PubMed ID: 29593436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repetitive transcranial magnetic stimulation for the treatment of amyotrophic lateral sclerosis or motor neuron disease.
    Fang J; Zhou M; Yang M; Zhu C; He L
    Cochrane Database Syst Rev; 2013 May; 2013(5):CD008554. PubMed ID: 23728676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis.
    Andrews JA; Meng L; Kulke SF; Rudnicki SA; Wolff AA; Bozik ME; Malik FI; Shefner JM
    JAMA Neurol; 2018 Jan; 75(1):58-64. PubMed ID: 29181534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.